Dear Expert,

We are conducting a consensus survey to establish expert recommendations on minimal residual disease (MRD)-adapted therapy, focusing on clinical practice in multiple myeloma (MM). Your valuable insights will help guide clinical practice in this field. The consensus survey is divided into 4 sections, and we kindly ask you to provide your expert opinions for each by March 1st.

Please note that all responses are confidential and will be analyzed anonymously. We sincerely appreciate your time and expertise.